Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience

Prognostic value of preoperative inflammatory response biomarkers in patients with sarcomatoid renal cell carcinoma and the establishment of a nomogram

(2016) Liangyou Gu et al.   Scientific Reports

Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients

(2016) Xiaobin Gu et al.   Scientific Reports

Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer

(2014) D J Pinato et al.   BRITISH JOURNAL OF CANCER

Epidemiologic and Molecular Prognostic Review of Glioblastoma

(2014) J. P. Thakkar et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

(2014) Arnoud J. Templeton et al.   JNCI-Journal of the National Cancer Institute

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme

(2013) R. M. Bambury et al.   JOURNAL OF NEURO-ONCOLOGY

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

(2012) L. R. Molife et al.   ANNALS OF ONCOLOGY

Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

(2011) Ignacio Garrido-Laguna et al.   CANCER

Inclusion of Patients with Brain Metastases in Phase I Trials: An Unmet Need

(2011) M. M. Gounder et al.   CLINICAL CANCER RESEARCH

Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkinʼs Lymphoma

(2011) Andrzej Hellmann et al.   CLINICAL PHARMACOKINETICS

It Is Time to Include Patients With Brain Tumors in Phase I Trials in Oncology

(2011) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma

(2011) Lola B. Chambless et al.   JOURNAL OF NEURO-ONCOLOGY

Revisiting the role of molecular targeted therapies in patients with brain metastases

(2011) Dionysis Papadatos-Pastos et al.   JOURNAL OF NEURO-ONCOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Diabetes and cancer

(2009) Paolo Vigneri et al.   ENDOCRINE-RELATED CANCER

Association Between Hyperglycemia and Survival in Patients With Newly Diagnosed Glioblastoma

(2009) Rachel L. Derr et al.   JOURNAL OF CLINICAL ONCOLOGY

PERSISTENT OUTPATIENT HYPERGLYCEMIA IS INDEPENDENTLY ASSOCIATED WITH DECREASED SURVIVAL AFTER PRIMARY RESECTION OF MALIGNANT BRAIN ASTROCYTOMAS

(2009) Matthew J. McGirt et al.   NEUROSURGERY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY